Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation

Circulation

Volumn 96, Issue 2, 1997, Pages 628-635

  Zhu, Nian Ling ^a   Wu, Lingtao ^a   Liu, Peng Xuan ^a   Gordon, Erlinda M ^a   Anderson, W French ^a   Starnes, Vaughn A ^a   Hall, Frederick L ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Angioplasty; Cyclin G1; Genes; Muscle, smooth

Indexed keywords

CYCLIN G1; CYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; WOUND HEALING;

EID: 0012299086     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.2.628     Document Type: Article

References (47)

1. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation. 1994;89:2888-2891.
2. Schwartz RS, Holmes DR, Topol J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;17:1284-1293.
3. Myers P. Vascular wound healing and restenosis following revascularization. In: Weber KT, ed. Wound Healing Responses in Cardiovascular Disease. Mt Kisco, NY: Futura Publishing Co; 1995: 137-150.
4. Schwartz SM, deBlois D, O'Brien ERM. The intima. Cire Res. 1995;77:445-465.
5. Meininger GA, Davis MJ. Cellular mechanisms involved in the vascular myogenic response. Am J Physiol. 1992;263:647-659.
6. Casscells W, Engler D, Willerson JT. Mechanisms of restenosis. Tex Heart Inst J. 1994;21:68-77.
7. Jackson Cl. Animal models of restenosis. Trends Cardiovasc Med. 1994;4:122-130.
8. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;6:369-375.
9. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol. 1991;17:433-439.
10. Waller BF, Pinkerton CA, Orr CM, Slack JD, Van Tassel JW, Peters T. Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients. J Am Coll Cardiol. 1991;17:58B-70B.
11. Ueda M, Becker AE, Tsukada T, Numano F, Fujimoto T. Fibrocellular response after percutaneous transluminal coronary angioplasty: an immunocytochemical analysis of the cellular composition. Circulation. 1991;83:1327-1332.
12. Reidy MA. Regulation of arterial smooth muscle growth. In: Schwartz SM, Mecham RP, eds. The Vascular Smooth Muscle Cell. New York, NY: Academic Press, Inc; 1995:271-295.
13. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 1993;69:S30-S37.
14. Schwartz SM, O'Brien ER, deBlois D, Giachelli CM. Relevance of smooth muscle replication and development to vascular disease. In: Schwartz SM, Mecham RP, eds. The Vascular Smooth Muscle Cell. New York, NY: Academic Press, Inc; 1995:81-139.
15. Rubin K, Hanson KG, Roennstrand L, Claesson-Welsh L, Fellstroem B, Tingstroem A, Larson E, Klareskog E, Heldin CH, Terracio L. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet. 1988;1:1353-1356.
16. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor β1 is increased in human vascular restenosis lesions. J Clin Invest. 1992;90:1582-1592.
17. Nabel EG, Shum L, Pompili VJ, Yang Z, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel G. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
18. Nabel EG, Yang Z, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature. 1993;362:844-846.
19. Murphy LJ, Ghahary JA, Chakrabart S. Insulin regulation of IGF-1 expression in rat aorta. Diabetes. 1990;39:657-662.
20. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.
21. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von de Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau V. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
22. Chang MW, Barr E, LU MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
23. Wu L, Liu L, Yee A, Tolo VT, Hall F. Molecular cloning of the human CYCG1 gene encoding G-type cyclin: overexpression in human osteosarcoma cells. Oncol Rep. 1994;1:705-711.
24. Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 1995;55:5493-5498.
25. Lal B, Cahan MA, Couraud PO, Goldstein GW, Laterra J. Development of endogenous β-galactosidase and autofluorescence in rat brain microvessels: implications for cell tracking and gene transfer studies. J Histochem Cytochem. 1994;42:953-956.
26. Gordon EM, Venkatesan N, Salazar R, Tang H, Schmeidler-Sapiro K, Buckley S, Warburton D, Hall F. Proc Natl Acad Sci U S A. 1996;93:2174-2179.
27. Williams R, Wu L, Carbonaro-Hall D, Tolo V, Hall F. Identification of a novel cyclin-like protein in human tumor cells. J Biol Chem. 1993;268:8871-8880.
28. Wu L, Williams RT, Carbonaro-Hall DA, Liu L, Tolo VT, Hall FL. Sequential and progressive cyclin expression in human osteosarcoma cells: diagnostic and therapeutic implications. Int J Oncol. 1993;3:859-867.
29. Colton TE. Inference on means. In: Statistics in Medicine. Boston, Mass: Little, Brown & Co; 1974:99.
30. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276-5281.
31. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990;249:1285-1288.
32. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995;25:362-369.
33. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science. 1996;272:689-693.
34. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A. 1995;92:4502-4506.
35. Abe J, Zhou W, Taguchi J, Takuwa N, Miki K, Okazaki H, Kurokawa K, Kumada M, Takuwa Y. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun. 1994;198:16-24.
36. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
37. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
38. Albers M, Brown E, Tanaka A, Williams R, Hall F, Schreiber S. Ann N Y Acad Sci. 1993;696:54-62.
39. Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL. FKBP-rapamycin inhibits a cyclin-dependent kinase activity in early G1 of a human osteosarcoma cell line. J Biol Chem. 1993;268: 22825-22829.
40. Jayaraman T, Marks AR. Rapamycin-FKBP12 blocks proliferation, induces differentiation and inhibits cdc2 kinase activity in a myogenic cell line. J Biol Chem. 1993;34:25385-25388.
41. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-661.
42. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
43. 1 phase progression: cycling on cue. Cell. 1994;79: 551-555.
44. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 1994;13:4816-4822.
45. Jones JS, Risser R. Cell fusion induced by the murine leukemia virus envelope glycoprotein. J Virol. 1993;67:67-74.
46. Pollman MJ, Sherwood SW, Gibbons GH. Cell cycle arrest induces vascular smooth muscle cell programmed cell death: implications for antiproliferative therapies for restenosis. Circulation. 1995;92(suppl I):I-101.
47. Biro S, Fu Y, Yu Z, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993;90: 654-658.